Big Pharma's traditional hands-off approach led to a serious credibility issue for Novartis as a data manipulation scandal has unfolded at gene therapy biotech AveXis. Going forward, Novartis says, it will be hands-off no longer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,